DexCom Securities Suits Intensify as Firms Seek Lead Plaintiffs

Overview

• Kessler Topaz, Levi & Korsinsky, and Bernstein Liebhard cite a December 26 deadline to move for lead plaintiff, while Rosen sets a December 29 cutoff.
• The overlapping class periods include January 8, 2024 to September 17, 2025 and July 26, 2024 to September 17, 2025, affecting who may participate.
• Complaints allege DexCom made unapproved design changes to its G6 and G7 glucose monitors that reduced reliability and created health risks.
• Filings contend the company overstated G7 performance and minimized issues, with investors claiming losses when the details reached the market.
• Notices emphasize that no class has been certified and that the ability to share in any recovery does not depend on serving as lead plaintiff.